Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online:424
  • Home
  • Print this page
  • Email this page
Year : 2019  |  Volume : 33  |  Issue : 2  |  Page : 71-76

Targeting the therapeutic need in musculoskeletal inflammatory pain with thiocolchicoside and aceclofenac sustained-release combination therapy

Department of Scientific, Aristo Pharmaceuticals Private Limited, Mumbai, Maharashtra, India

Correspondence Address:
Dr. Manish N Maladkar
Aristo Pharmaceuticals Private Limited, 23-A, Shah Industrial Estate, Off Veera Desai Road, Andheri (West), Mumbai - 400 053, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijpn.ijpn_23_19

Rights and Permissions

Context: Musculoskeletal pain is usually associated with inflammation and muscular spasm which further contributes to the elevation of pain. Traditionally, nonsteroidal anti-inflammatory drugs (NSAIDs) are employed in the treatment of pain. Literature review reveals that the benefits were more significant in terms of overall symptom reduction, when the patients suffering from musculoskeletal pain were administered the combination of a NSAID & a muscle relaxant. Aims: The present study was undertaken with the aim to assess the efficacy and safety of fixed-dose sustained-release combination of aceclofenac and thiocolchicoside in patients with acute inflammatory conditions associated with muscle spasm. Settings and Design: A multicenter, prospective, open-label, noncomparative clinical study was carried out in 442 patients with clinical diagnosis of inflammation associated with spasm. Subjects and Methods: fixed-dose combination of aceclofenac (200 mg) and thiocolchicoside (8 mg)-sustained-release capsules was orally administered once daily for 2 weeks. Results: The treatment led to significant pain reduction from the baseline noted with visual analog score at the 1st week itself. After 2 weeks of treatment, the mean pain score declined by 90%, joint tenderness improved in 90% of the patients, and the mean joint mobility scores were near normal in most of the patients. Furthermore, at the end of the treatment, nearly all of the patients were symptom free. No serious adverse events were reported. Conclusions: The current study confirms that fixed-dose combination of aceclofenac and thiocolchicoside in sustained-release form is effective and well tolerated in the treatment of patients with acute musculoskeletal inflammatory conditions.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded475    
    Comments [Add]    

Recommend this journal